LYEL (38) RCKT (31) GLSI (41) BIOA (44) ⌘ Pro Terminal →

Larimar Therapeutics Inc. (LRMR) — RQD Stock Rating Cockpit

$2.67 +5.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.69

Larimar Therapeutics Inc. (LRMR) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY) →

ROARABLE D • SELL / AVOID Cap $277.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.69 (+0.73%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-3.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LRMR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (50/100 Composite)

🔍 WHY LRMR SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (30% of score)

FRED Regime × Technicals: 17% of 52W Range • RSI-14 at 43.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.67-25.5% Next Q

Q2 (-2Q)

Grade D$1.99+18.1% Next Q

Q3 (-1Q)

Grade D$2.35+13.6% Next Q

Current

Grade D$2.67-1.4% Hist 90D α

Trajectory: D (42) → D (50)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LRMR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LRMR currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.21) and Max Pain ($2.80) forces dealer call-delta covering toward $6.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LRMR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LRMR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 50%NO 50%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

43.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE17% OF RANGE

L: $2$2.67H: $6

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on LRMR

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (53)

17/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like LRMR

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LRMR)

✓Walkthrough of LRMR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LRMR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.24%📐 HORIZONTAL RANGE

2026-10-30O $2.64H $2.67L $2.42C $2.67VOL 781.0K

RES: $5.40SUP: $1.79SMA50: $3.21SMA200: $3.81

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LRMR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LRMR Butterfly Map → + Track LRMR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LRMR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LRMR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LRMR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LRMR)

Health Care Rank #346 of 1016 ⚔️ LYEL vs LRMR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LRMR vs. LYEL, RCKT, GLSI, BIOA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Larimar Therapeutics Inc. (LRMR) ranks #346 by composite RQD confidence (50/100, grade D) and #530 by equity capitalization ($277.4M). Within this direct 5-issuer industry benchmark cohort, LRMR leads on earnings valuation at N/A trailing P/E, while LRMR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LRMR currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LRMR ACTIVE Larimar Therapeutics Inc.	D	50/100	—	—	-35.0%	+5.12%	$277.4M	Benchmark Subject
LYEL Lyell Immunopharma Inc.	D-	38/100	—	—	-35.0%	+3.43%	$277.0M	/lyel-vs-lrmr →
RCKT Rocket Pharmaceuticals Inc.	E	31/100	—	—	-35.0%	-1.55%	$278.8M	/rckt-vs-lrmr →
GLSI Greenwich LifeSciences Inc.	D-	41/100	—	—	-35.0%	+3.77%	$278.9M	/glsi-vs-lrmr →
BIOA BioAge Labs Inc.	D	44/100	—	—	-35.0%	0.00%	$272.6M	/bioa-vs-lrmr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001374690

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Larimar Therapeutics Inc. (LRMR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$165.7M, operating cash flow of -$113.2M, and free cash flow of -$113.3M (-59.0% YoY). On the balance sheet, LRMR closed FY2025 with $145.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$165.7M	-$113.2M	-$113.3M	$145.8M	—
FY2024 (FY)	2024-12-31	$0	-$80.6M	-$70.8M	-$71.3M	$200.2M	—
FY2023 (FY)	2023-12-31	$0	-$36.9M	-$33.5M	-$33.5M	—	—

3. LRMR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LRMR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Larimar Therapeutics Inc. (NASDAQ: LRMR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $2.67 (+5.12% 1D, market cap $277.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LRMR ranks #346 in composite RQD confidence.

How does LRMR compare to LYEL and RCKT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LRMR carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LYEL (Lyell Immunopharma Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $277.0M) and RCKT (Rocket Pharmaceuticals Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $278.8M). Among the 5-stock peer group, LRMR leads on earnings multiple (N/A) while LRMR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LRMR?

Per LRMR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001374690), Larimar Therapeutics Inc. generated $0 in revenue, -$165.7M in net income, and -$113.3M in free cash flow against $145.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LRMR trading relative to its 50-day, 200-day, and 52-week technical levels?

LRMR last traded at $2.67 (+5.12% on volume of 1,027,353 shares), positioning the stock -16.82% below its 50-day simple moving average ($3.21) and -29.92% below its 200-day simple moving average ($3.81). Across its 52-week range of $1.92 to $6.42, LRMR sits at the 16.7% percentile with a 14-day RSI of 43.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.34 to $3.00).

LRMR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell LRMR stock right now?

Larimar Therapeutics Inc. (LRMR) currently earns a Roarable Rating of D (Sell — SELL) with 50/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is LRMR's 12-month price target and RQD AI Jury consensus?

LRMR's 12-month base price target is $2.57 (range $2 to $6.74), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: LRMR RQD Cockpit LRMR 12M Forecast LRMR Earnings & Move LRMR Dividends & DRIP LRMR Insiders & 13F LRMR Whale Options LRMR Profit Sankey LRMR News & Why